Marshall Wace’s Ocular Therapeutix OCUL Stock Holding History

Marshall Wace’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Sell	126,033 -614,770	-83%	-$5.57M	﹤0.01%	2093
2026 Q1	$6.27M	Sell	740,803 -636,400	-46%	-$6.07M	0.01%	1193
2025 Q4	$16.7M	Sell	1,377,203 -224,246	-14%	-$2.72M	0.02%	692
2025 Q3	$18.7M	Buy	+1,601,449	New	+$19.1M	0.02%	680
2024 Q4	–	Sell	-87,743	Closed	-$763K	–	2884
2024 Q3	$763K	Sell	87,743 -341,849	-80%	-$2.82M	﹤0.01%	1765
2024 Q2	$2.94M	Buy	+429,592	New	+$2.65M	﹤0.01%	1204
2023 Q3	–	Sell	-15,149	Closed	-$78.2K	–	2544
2023 Q2	$78.2K	Buy	+15,149	New	+$90.1K	﹤0.01%	2348
2022 Q4	–	Sell	-531,636	Closed	-$2.21M	–	3277
2022 Q3	$2.21M	Buy	+531,636	New	+$2.68M	﹤0.01%	1941
2021 Q4	–	Sell	-89,335	Closed	-$893K	–	4173
2021 Q3	$893K	Buy	89,335 +76,221	+581%	+$856K	﹤0.01%	2088
2021 Q2	$186K	Buy	+13,114	New	+$199K	﹤0.01%	2461
2020 Q2	–	Sell	-32,533	Closed	-$161K	–	1840
2020 Q1	$161K	Buy	+32,533	New	+$161K	﹤0.01%	1222

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's OCUL Position: Q2 2026 in Review

Marshall Wace reduced its Ocular Therapeutix (OCUL) stake by 83% in Q2 2026, selling an estimated $5.57M and leaving 126,033 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Marshall Wace first reported a position in OCUL in Q1 2020 and has held it in 11 quarters since. The position peaked at $18.7M in Q3 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Marshall Wace held 126,033 shares of Ocular Therapeutix worth $1.24M as of Q2 2026.
Marshall Wace sold 614,770 Ocular Therapeutix shares in Q2 2026, an estimated $5.57M.
Ocular Therapeutix made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2093 holding.
Marshall Wace first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 11 quarters since.
Marshall Wace's Ocular Therapeutix position peaked at $18.7M in Q3 2025.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.